Breath Analysis Based Disease Biomarkers
- Conditions
- COVID19Liver DiseasesLiver Cancer
- Interventions
- Diagnostic Test: Collection of breath sample
- Registration Number
- NCT04341012
- Lead Sponsor
- Mayo Clinic
- Brief Summary
The purpose of the study is to develop a clinical test based on breath analysis that can be used for disease diagnosis or prognosis.
- Detailed Description
The study will seek to collect and analyze breath samples from a broad range of patients to develop reference ranges and to refine the testing methods. Protocols for breath sample collection and algorithms for analysis will be developed. Samples will be collected from normal volunteers, persons with documented liver disease, organ transplant or with known COVID-19 test results.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 46
- Able to provide informed consent
- None
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Other Collection of breath sample Persons with other medical diagnosis, no known liver disease, negative for COVID-19 COVID-19 tested Collection of breath sample Persons with known test results for COVID-19 RNA Normal Collection of breath sample No known medical conditions Liver Cirrhosis Collection of breath sample Clinically diagnosed with cirrhosis
- Primary Outcome Measures
Name Time Method Breath Volatile Organic Compound Profiles 1 day Detection of profiles of volatile organic compounds present in exhaled breath. The values in the table represent the number of participants from whom a volatile organic compound profile was able to be detected.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Mayo Clinic Florida
🇺🇸Jacksonville, Florida, United States